Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new ...

Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for ...

Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...

We recently compiled a list of the 20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years. In this article, we ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

We recently published a list of Top 10 Stocks to Buy According to Sustainable Insight Capital Management. In this article, we ...